Logo image of BBNX

BETA BIONICS INC (BBNX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BBNX - US08659B1026 - Common Stock

31.42 USD
+3.02 (+10.63%)
Last: 11/21/2025, 8:13:17 PM
31.42 USD
0 (0%)
After Hours: 11/21/2025, 8:13:17 PM
Fundamental Rating

4

BBNX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. BBNX has a great financial health rating, but its profitability evaluates not so good. BBNX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BBNX has reported negative net income.
BBNX had a negative operating cash flow in the past year.
BBNX Yearly Net Income VS EBIT VS OCF VS FCFBBNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -23.59%, BBNX is in line with its industry, outperforming 49.47% of the companies in the same industry.
BBNX has a better Return On Equity (-26.41%) than 60.11% of its industry peers.
Industry RankSector Rank
ROA -23.59%
ROE -26.41%
ROIC N/A
ROA(3y)-86.31%
ROA(5y)N/A
ROE(3y)-215.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBNX Yearly ROA, ROE, ROICBBNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

With a Gross Margin value of 54.51%, BBNX perfoms like the industry average, outperforming 51.60% of the companies in the same industry.
BBNX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BBNX Yearly Profit, Operating, Gross MarginsBBNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 -10K -20K -30K

More info and screens

9

2. Health

2.1 Basic Checks

BBNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BBNX has about the same amount of shares outstanding.
BBNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BBNX Yearly Shares OutstandingBBNX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M
BBNX Yearly Total Debt VS Total AssetsBBNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M

2.2 Solvency

BBNX has an Altman-Z score of 22.18. This indicates that BBNX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 22.18, BBNX belongs to the top of the industry, outperforming 96.28% of the companies in the same industry.
BBNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 22.18
ROIC/WACCN/A
WACC8.7%
BBNX Yearly LT Debt VS Equity VS FCFBBNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

BBNX has a Current Ratio of 10.64. This indicates that BBNX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BBNX (10.64) is better than 95.21% of its industry peers.
A Quick Ratio of 9.83 indicates that BBNX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 9.83, BBNX belongs to the best of the industry, outperforming 93.62% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.64
Quick Ratio 9.83
BBNX Yearly Current Assets VS Current LiabilitesBBNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for BBNX have decreased strongly by -24.17% in the last year.
The Revenue has grown by 442.93% in the past year. This is a very strong growth!
EPS 1Y (TTM)-24.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)442.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 9.42% on average over the next years. This is quite good.
The Revenue is expected to grow by 39.42% on average over the next years. This is a very strong growth
EPS Next Y4.7%
EPS Next 2Y6.68%
EPS Next 3Y4.06%
EPS Next 5Y9.42%
Revenue Next Year49.72%
Revenue Next 2Y42.73%
Revenue Next 3Y39.39%
Revenue Next 5Y39.42%

3.3 Evolution

BBNX Yearly Revenue VS EstimatesBBNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
BBNX Yearly EPS VS EstimatesBBNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BBNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BBNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBNX Price Earnings VS Forward Price EarningsBBNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBNX Per share dataBBNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.68%
EPS Next 3Y4.06%

More info and screens

0

5. Dividend

5.1 Amount

BBNX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BETA BIONICS INC

NASDAQ:BBNX (11/21/2025, 8:13:17 PM)

After market: 31.42 0 (0%)

31.42

+3.02 (+10.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-28 2025-10-28/amc
Earnings (Next)03-23 2026-03-23
Inst Owners101.26%
Inst Owner Change-85.37%
Ins Owners0.64%
Ins Owner Change-0.48%
Market Cap1.37B
Revenue(TTM)88.57M
Net Income(TTM)-77.84M
Analysts86.25
Price Target31.93 (1.62%)
Short Float %8.66%
Short Ratio4.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.14%
Min EPS beat(2)14.89%
Max EPS beat(2)25.39%
EPS beat(4)2
Avg EPS beat(4)-130.42%
Min EPS beat(4)-470.41%
Max EPS beat(4)25.39%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)13.6%
Min Revenue beat(2)11.46%
Max Revenue beat(2)15.74%
Revenue beat(4)3
Avg Revenue beat(4)7.72%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)15.74%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)32.25%
PT rev (3m)32.25%
EPS NQ rev (1m)6.89%
EPS NQ rev (3m)7.13%
EPS NY rev (1m)6.24%
EPS NY rev (3m)6.24%
Revenue NQ rev (1m)9.22%
Revenue NQ rev (3m)9.58%
Revenue NY rev (1m)6.36%
Revenue NY rev (3m)6.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.42
P/FCF N/A
P/OCF N/A
P/B 4.63
P/tB 4.63
EV/EBITDA N/A
EPS(TTM)-4.37
EYN/A
EPS(NY)-1.83
Fwd EYN/A
FCF(TTM)-1.39
FCFYN/A
OCF(TTM)-1.3
OCFYN/A
SpS2.04
BVpS6.78
TBVpS6.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -23.59%
ROE -26.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.51%
FCFM N/A
ROA(3y)-86.31%
ROA(5y)N/A
ROE(3y)-215.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 915.51%
Cap/Sales 4.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.64
Quick Ratio 9.83
Altman-Z 22.18
F-Score6
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)128.38%
Cap/Depr(5y)N/A
Cap/Sales(3y)146.62%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y4.7%
EPS Next 2Y6.68%
EPS Next 3Y4.06%
EPS Next 5Y9.42%
Revenue 1Y (TTM)442.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year49.72%
Revenue Next 2Y42.73%
Revenue Next 3Y39.39%
Revenue Next 5Y39.42%
EBIT growth 1Y-26.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-47.67%
EBIT Next 3Y-14.5%
EBIT Next 5Y0.31%
FCF growth 1Y-57.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.78%
OCF growth 3YN/A
OCF growth 5YN/A

BETA BIONICS INC / BBNX FAQ

What is the fundamental rating for BBNX stock?

ChartMill assigns a fundamental rating of 4 / 10 to BBNX.


Can you provide the valuation status for BETA BIONICS INC?

ChartMill assigns a valuation rating of 0 / 10 to BETA BIONICS INC (BBNX). This can be considered as Overvalued.


What is the profitability of BBNX stock?

BETA BIONICS INC (BBNX) has a profitability rating of 1 / 10.


How financially healthy is BETA BIONICS INC?

The financial health rating of BETA BIONICS INC (BBNX) is 9 / 10.